STOCK TITAN

AngioDynamics shareholders approve equity plan expansion

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

AngioDynamics (ANGO) shareholders approved an amendment to the 2020 Equity Incentive Plan at the November 17, 2026 annual meeting, increasing the shares available for issuance. The amendment received 26,990,852 votes for and 3,784,918 against. Shareholders also approved the advisory executive-compensation proposal, with 29,073,414 votes for and 1,691,653 against, and ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending May 31, 2027. Eileen O. Auen and Jan Stern Reed were elected as Class II directors to serve until the 2029 annual meeting and until their successors are elected and qualified.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
2020 Equity Incentive Plan votes for 26,990,852 votes Shareholder vote on November 17, 2026
2020 Equity Incentive Plan votes against 3,784,918 votes Shareholder vote on November 17, 2026
Executive-compensation votes for 29,073,414 votes Advisory shareholder vote on November 17, 2026
Executive-compensation votes against 1,691,653 votes Advisory shareholder vote on November 17, 2026
Auditor-ratification votes for 36,287,806 votes Ratification of Deloitte & Touche LLP for the fiscal year ending May 31, 2027
Eileen O. Auen votes for 28,252,245 votes Class II director election
Jan Stern Reed votes for 27,956,254 votes Class II director election
broker non-votes technical
"Broker non-votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
advisory basis regulatory
"approve, on an advisory basis, AngioDynamics’ executive compensation"
2020 Equity Incentive Plan financial
"amended AngioDynamics, Inc. 2020 Equity Incentive Plan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many votes did AngioDynamics’ amended equity plan receive?

The amended 2020 Equity Incentive Plan received 26,990,852 votes for and 3,784,918 against at the November 17, 2026 annual meeting.

Which AngioDynamics directors were elected, and how many votes did they receive?

Eileen O. Auen and Jan Stern Reed were elected as Class II directors. Auen received 28,252,245 votes for and 2,555,472 withheld; Reed received 27,956,254 votes for and 2,851,463 withheld. Each is to serve until the 2029 annual meeting and until a successor is elected and qualified.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 

 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): November 17, 2026
 
AngioDynamics, Inc.
(Exact Name of Registrant as Specified in Charter)
 
Delaware
000-50761
11-3146460
 
 
 
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
 
  
14 Plaza Drive, Latham, New York 12110
   
(Address of Principal Executive Offices) (Zip Code)
 
(518) 795-1400
(Registrant’s telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading Symbol(s)
 
Name of each exchange on which
registered
Common Stock, par value $0.01 per share
 
ANGO
 
NASDAQ Global Select Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

1

 
Item 5.02-
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
(e)
As described below, the shareholders of AngioDynamics, Inc. (“AngioDynamics”) voted on November 17, 2026 to approve the amended AngioDynamics, Inc. 2020 Equity Incentive Plan (the “2020 Plan”) to increase the number of shares available for issuance. The material terms of the 2020 Plan are described in Proposal 4 included in AngioDynamics’ definitive proxy statement filed with the Securities and Exchange Commission on October 8, 2026, which description does not purport to be complete and is qualified in its entirety by reference to the full text of the 2020 Plan, which is attached as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.
 
Item 5.07-
Submission of Matters to a Vote of Security Holders.
 
(a)
The Annual Meeting of Shareholders of AngioDynamics was held on November 17, 2026.
 
(b)
Shareholders of AngioDynamics voted on the matters set forth below.
 
1.
The nominees for election to the Board of Directors were elected, each as a Class II director to serve until the 2029 Annual Meeting of Shareholders and until their respective successors are duly elected and qualified, based upon the following votes:
 
Nominee
Votes For
Withheld
Broker Non-Votes
Eileen O. Auen
28,252,245
2,555,472
5,872,140
Jan Stern Reed
27,956,254
2,851,463
5,872,140
 
2.
The proposal to ratify the appointment of Deloitte & Touche LLP as AngioDynamics’ independent registered public accounting firm for the fiscal year ending May 31, 2027 was approved based upon the following votes:
 
Votes for approval
36,287,806
Votes against
381,289
Abstentions
10,762
 
There were no broker non-votes for this item.
 
3.
The proposal to approve, on an advisory basis, AngioDynamics’ executive compensation of its named executive officers was approved based upon the following votes:
 
Votes for approval
29,073,414
Votes against
1,691,653
Abstentions
42,650
Broker non-votes
5,872,140
 
4.
The proposal to approve the amended AngioDynamics, Inc. 2020 Equity Incentive Plan was approved based upon the following votes:
 
Votes for approval
26,990,852
Votes against
3,784,918
Abstentions
31,947
Broker non-votes
5,872,140
 
2

 
(c)
Not applicable.
 
(d)
Not applicable.
 
Item 9.01
Financial Statements and Exhibits.
 
Exhibits.
 
Exhibit No.
Description
 
 
10.1
AngioDynamics, Inc. 2020 Equity Incentive Plan, as amended (incorporated by reference to Appendix A of the Registrant’s Definitive Proxy Statement filed on October 8, 2026 in connection with the Annual Meeting held on November 17, 2026 (File No. 000-50761)).
 
3

 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
 
ANGIODYNAMICS, INC.
 
(Registrant)
 
 
 
Date: November 18, 2026
By:
/s/ Lawrence T. Weiss
 
 
Name: Lawrence T. Weiss
 
 
Title: Senior Vice President, Chief Legal Officer and Corporate Secretary
 
 

0001275187 false 0001275187 2026-11-17 2026-11-17

Filing Exhibits & Attachments

3 documents

Keep reading